The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer

International Journal of Gynecological Pathology

Volumn 18, Issue 1, 1999, Pages 42-51

  Anttila, Maarit A ^a,b   Ji, Hongxiu ^a   Juhola, Matti T ^c   Saarikoski, Seppo V ^a   Syrjänen, Kari J ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c NONE

Author keywords

Image analysis; Immunohistochemistry; Ovarian cancer; p53

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COMPUTER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 0032959152     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199901000-00006     Document Type: Article

References (46)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
2. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6
3. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992;84:845-55
4. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31
5. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62
6. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AKC. Cytoplasmic accumulation of p53 protein: an independent prognostic factor in colorectal adenomas. J Natl Cancer Inst 1994; 86:681-7
7. Berchuk A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obster Gynecol 1994;170:246-52
8. Montenarh M. Biochemical properties of the growth suppressor/ oncoprotein p53. Oncogene 1992;7:1673-80
9. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27
10. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51: 2979-84
11. Kupryjanczyk J, Thor AD, Beauchamp R, Merrit V, Edgerton SM, Bell DA. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5
12. Kohler MF, Kerns B-JM, Humphrey PA, Marks JR, Bast RC, Berchuk A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-50
13. Bartek J, Bartkova J, Vojtesek B. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of malignancies. Oncogene 1991;6:1699-1703
14. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38
15. Klemi P-J, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76: 1201-8
16. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994;172:1-4
17. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988;90: 233-9
18. Cancer Committee of the International Federation of Gynecology and Obstetrics. Staging announcement: FIGO Cancer Committee. Gynecol Oncol 1986;25:383-5
19. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumors. Geneve: World Health Organization, 1973:9.
20. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuk A. P53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175:1246-52
21. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-6
22. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-9
23. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84
24. Lee AKC, Dugan J, Hamilton WM, Cook L, Heatley G, Kamat B, Silverman ML. Quantitative DNA analysis in breast carcinomas: a comparison between image analysis and flowcytometry. Mod Pathol 1991;4:178-82
25. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7
26. Shiina H, Igawa M, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer. Oncology 1996; 53:233-40.
27. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-9
28. Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Crowther B. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer 1994;69:609-12
29. van der Zee AGJ, Hollema H, Suurmeijer AJH, et al. Value of p-glycoprotein, glutathione S-transferase pi, c-erbB-2 and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13: 70-8
30. McManus DT, Yap EPH, Maxwell P, Russell SEH, Toner PG, McGee JOD. p53 expression, mutation and allelic deletion in ovarian cancer. J Pathol 1994;174:159-68
31. Holm R, Niesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172:267-72
32. Tan LK, Dowell SP, Ogden GR. Antigen retrieval: p53 staining in benign, pre-malignant and malignant tissue of the larynx. Clin Otolaryngol 1996;21:147-50
33. Lane DP, Crawford LV. T antigen is bound to a host protein in SV 40-transformed cells. Nature 1979;278:261-3
34. Nishio M, Koshikawa T, Kuroishi T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996;14:497-502
35. Melhem MP, El-Ashmawy L, Johnson JT, Landrenau RJ, Shrivastava S, Whiteside TL. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146:1170-7
36. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, Löning T. p53 mutations in ovarian tumours, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 1995;64: 52-9
37. Harlozinska A, Bar JK, Sedlaczek P, Gerber J. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Am J Clin Pathol 1996;105:334-40
38. Kerns BJ, Jordan PA, Moore MB, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-51
39. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994; 13:311-8
40. Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. Unifocal origin of advanced human epithelial ovarian cancer. Cancer Res 1992;52:5119-22
41. Henriksen R, Strang P, Wilander E, Bäckström T, Tribukait B, Öberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6
42. Green JA, Robertson LJ, Campbell IR, Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995;19: 151-5
43. Buttita F, Marchetti A, Gadducci A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5
44. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93
45. Geisler JP, Geisler HE, Wiemann MC. Givens SS, Zhou Z, Miller GA. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997;66:435-8
46. Shelling AN. Role of p53 in drug resistance in ovarian cancer. Lancet 1997;349:744-5